Approximately 792,142 units of Rizatriptan Benzoate (generic Maxalt) tablets are being recalled because testing identified organic impurities that did not meet quality standards. The recall includes various strengths of film-coated and orally disintegrating tablets used to treat migraine symptoms. These prescription medications were distributed nationwide across the United States in blister packs containing 12 or 18 tablets.
The presence of out-of-specification organic impurities means the drug may contain substances that were not intended to be in the final product, which could potentially affect the safety or effectiveness of the medication over time.
Contact healthcare provider and return product for refund.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.